Cure of ADPKD by Selection for Spontaneous Genetic Repair Events in Pkd1-Mutated iPS Cells by Cheng, Li-Tao et al.
Cure of ADPKD by Selection for Spontaneous Genetic
Repair Events in Pkd1-Mutated iPS Cells
Li-Tao Cheng
1,2, Shogo Nagata
1,3, Kunio Hirano
1, Shinpei Yamaguchi
1,3, Shigeo Horie
4, Justin
Ainscough
5, Takashi Tada
1,3*
1Stem Cell Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto Japan, 2Department of Nephrology, Peking University Third Hospital, Beijing,
China, 3JST CREST, Kawaguchi, Saitama, Japan, 4Department of Urology, Teikyo University, Tokyo, Japan, 5Cardiovascular and Neuronal Remodelling, LIGHT, Leeds
University, Leeds, United Kingdom
Abstract
Induced pluripotent stem cells (iPSCs) generated by epigenetic reprogramming of personal somatic cells have limited
therapeutic capacity for patients suffering from genetic disorders. Here we demonstrate restoration of a genomic mutation
heterozygous for Pkd1 (polycystic kidney disease 1) deletion (Pkd1(+/2) to Pkd1(+/R+)) by spontaneous mitotic recombi-
nation. Notably, recombination between homologous chromosomes occurred at a frequency of 1,2 per 10,000 iPSCs.
Southern blot hybridization and genomic PCR analyses demonstrated that the genotype of the mutation-restored iPSCs was
indistinguishable from that of the wild-type cells. Importantly, the frequency of cyst generation in kidneys of adult chimeric
mice containing Pkd1(+/R+) iPSCs was significantly lower than that of adult chimeric mice with parental Pkd1(+/2) iPSCs,
and indistinguishable from that of wild-type mice. This repair step could be directly incorporated into iPSC development
programmes prior to cell transplantation, offering an invaluable step forward for patients carrying a wide range of genetic
disorders.
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Introduction
Epigenetic reprogramming of personal somatic cells into iPSCs
by forced expression of defined transcription factors confers
pluripotency [1–3], but does not restore mutations that cause
genetic disorders. For therapeutic treatment of genetic disorders,
techniques using plasmid, zinc finger nucleases and helper-
dependent adenoviral vector-mediated homologous recombina-
tion have been developed to induce genetic editing in disease-
specific iPSCs and embryonic stem cells (ESCs) [4–9]. The
requirement for target gene-specific vectors coupled with inherent
low efficiency has restricted translation of the theoretical
possibilities to practical application of these techniques in iPSCs
for clinical therapy. Furthermore, Genetic modification in iPSCs
gives an obstacle to safety in clinical applications. Mitotic
recombination, which functions in DNA repair [10], occurs
at a low frequency (,10
26) in somatic cells [11]. However, in
experiments to drive targeted chromosome elimination from
pluripotent ES-somatic hybrid cells [12], evidence suggested the
frequency of genetic repair events through spontaneous mitotic
recombination in pluripotent stem cells is higher than that in
somatic cells [11]. Furthermore, chromosome-specific loss of
heterozygosity was created in a KO allele by high-dose G418
selection to the Neo gene in mouse embryonic stem cells [13].
Thus, we investigated whether it was possible to identify and
propagate isogenic clones of iPSCs, which retain the property of
infinite cell proliferation, in which spontaneously genetic correc-
tion had occurred at disease-related mutation alleles through
mitotic recombination (Figure 1).
Here, to demonstrate proof of principle for this theoretical
approach, we have investigated a prevalent inherited disorder,
autosomal dominant polycystic kidney disease (ADPKD).
ADPKD, which is caused by genetic mutation of the PKD1 and
PKD2 gene in 85% and 15% of cases, respectively [14], is clinically
diagnosed by intrarenal cystogenesis caused by complex mecha-
nisms. Deregulation of PKD1 or PKD2-coding polycystin protein
level results in initiation of cyst formation, followed by several
signaling pathways that mediate cyst growth and expansion [15].
Results and Discussion
iPSC lines were generated from mouse embryonic fibroblasts
(MEFs) derived from E12.5 Pkd1 knockout (KO)-heterozygous
embryos [16], through retroviral transduction of Oct4, Sox2, and
Klf4 (OSK) (Figure 1). The embryos were obtained by mating
C57BL/6 wild-type (+/+) mice with C57BL/6 Pkd1(+/2) mice.
Male Pkd1(+/2) MEFs were selected by genomic PCR analysis of
the Y-chromosome-specific Zfy gene prior to OSK viral transfec-
tion (Figure S1). Male iPSC lines, which were re-cloned following
GFP transfection, retained normal colony morphology and stable
expression of GFP marker (Figure 2a). Normal karyotype,
2n=40XY, was observed in 93 out of 104 (89.4%) cells examined
(Figure S2). Pluripotency of Pkd1(+/2) iPSCs was validated by
expression of pluripotent marker proteins, Oct4, Sox2, and Nanog
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pluripotent marker genes, Oct4, Sox2, Klf4, Nanog, Rex1, Gdf3,
Sall4, Dnmt3b, Klf2, and Dax1 by RT-PCR (Figure 2c). Colonies
amplified from single Pkd1(+/2) iPSCs by plating sparsely into
10 cm dishes were picked, expanded and screened by genomic
PCR using a Pkd1-specific primer set (Figure 1). Candidate clones
were secondary screened by genomic PCR with an additional
primer set specific to the KO allele-specific Neo gene (Figure 2d). In
total, more than 10,000 independent colonies were screened by
genomic PCR. Interestingly, two Pkd1(+/R+) clones lacking the
KO allele (Figure 2d), and one Pkd1(R2/2) clone lacking the
wild-type allele were detected. The frequency of spontaneous
mitotic recombination-mediated mutation repair event between
homologous chromosomes was estimated at 1.94610
24 for
Pkd1(+/R+) clone and 0.97610
24 for Pkd1(R2/2) clone
(Table 1). The spontaneous repair events between homologous
chromosomes occurred at the frequency, which could be
applicable to clinical applications.
To address the mechanism of allelic exchange at the Pkd1 locus,
DNA extracted from Pkd1(+/R+) iPSC lines was analyzed by
Southern blot hybridization with probe 1, 2, and 3 (Figure 2e).
Fragments for the KO allele, 7.8 kb with probe 1 and 7.0 kb with
probe 3, were detected in Pkd1(+/2) iPSCs but not wild-type or
Pkd1(+/R+) iPSCs, confirming loss of the Neo containing region.
The intensity of the 15.1 kb band for the wild-type allele, detected
by all three probes, was similar between wild-type and Pkd1(+/R+)
iPSCs, and reduced by approximately 50% in Pkd1(+/2) iPSCs,
when normalized against an internal loading control Stella,
demonstrating replacement of the KO allele with the wild-type
allele through mitotic recombination. To exclude the possibility of
wild-type cell contamination as a source of apparent Pkd1(+/R+)
iPSCs, Southern blot hybridization was performed with a probe
specific to Klf4 integrated as a multi-copy transgene in the iPSC
genome but not the wild-type genome (Figure 2f). Detection of the
same pattern of multiple bands in Pkd1(+/2) and Pkd1(+/R+)
iPSCs demonstrates that Pkd1(+/R+) iPSCs originated from
Pkd1(+/2) iPSCs.
To investigate the influence of mitotic recombination on Pkd1
expression, mRNA levels were analyzed by RT-PCR (Figure S3).
Expression in Pkd1(+/2) iPSCs was approximately half that in
WT or Pkd1(+/R+) iPSCs. Thus, expression of Pkd1 was restored
to the normal level in Pkd1(+/R+) iPSCs. Next, to examine
physiological effects of the restoration of the KO to wild-type
allele, chimeric mice were generated with Pkd1(+/2) and Pkd1(+/
R+) iPSCs, both of which exhibit ubiquitous GFP expression
(Figure 3a). Chimeras were analyzed at more than 6 months old
following established criteria for cystogenesis as reported previ-
ously, i.e. cyst diameter .200 mm [17]. Kidneys collected in
triplicate from mice generated with wild-type, Pkd1(+/2), and
Pkd1(+/R+) chimeric genotypes were sacrificed for histological
analyses. Extent of chimerism (22,48%) was comparable between
Pkd1(+/2) and Pkd1(+/R+) kidneys we examined (Figure 3b).
Cyst formation was frequently detected in the cortical region of the
Pkd1(+/2) chimeric kidneys but not the Pkd1(+/R+) and wild-
type kidneys (Figure S4). GFP-positive cells comprising part of the
cyst wall were observed in Pkd1(+/2) chimeric kidneys (Figure 3c),
indicating that unbalanced expression level of polycystin protein in
Pkd1(+/2) kidney cells might induce to initiate the cystogensis.
Figure 1. Scheme of in vitro screening and in vivo assay of mutation-restored Pkd1(+/R+) iPSCs. The knockout (KO) allele of Pkd1 is
spontaneously replaced with the wild-type allele through mitotic recombination occurring in rounds of cell division of Pkd1(+/2) iPSCs. Phenotype of
ADPKD (autosomal dominant polycystic kidney disease) caused by the mutation of Pkd1 is detected in kidneys from adult chimeric mice with Pkd1(+/
2), but not Pkd1(+/R+), iPSCs.
doi:10.1371/journal.pone.0032018.g001
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times higher in Pkd1(+/2), than Pkd1(+/R+) chimeric kidneys
(Figure 3d). The number of cysts detected in Pkd1(+/R+) chimeric
kidneys was comparable to that in wild-type kidneys. These data
clearly demonstrate that the mutation in Pkd1(+/2) iPSCs
involved in ADPKD was genetically and functionally restored in
Pkd1(+/R+) iPSCs through spontaneous mitotic recombination. It
is evident that selection of genetic mutation-restored iPSCs by
Figure 2. Screening of mutation-restored (Pkd1(+/R+)) iPSCs from iPSCs heterozygous for Pkd1 knockout (KO) (Pkd1(+/2)). a, Normal
colony morphology of Pkd1(+/2) iPSCs expressing fluorescence marker protein, GFP. b, Expression of pluripotent marker proteins, Oct4, Sox2, and
Nanog in Pkd1(+/R+) iPSCs by immunohistochemical analyses. c, Transcription of pluripotent marker genes in Pkd1(+/2) and Pkd1(+/R+) iPSCs by RT-
PCR analyses. d, Secondary screening of Pkd1(+/R+) iPSCs by genomic PCR analyses. e, Verification of replacement of the KO allele by the wild-type
(WT) allele through spontaneous mitotic recombination in Pkd1(+/R+) iPSCs by Southern blot hybridization analyses. Relative intensity is noted under
the 15.1 kb band. f, Determination of the origin of Pkd1(+/R+) iPSCs by Southern blot hybridization.
doi:10.1371/journal.pone.0032018.g002
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isogenic and functionally restored iPSCs safely for using clinical
applications.
Our results establish a paradigm for enrichment of iPSC clones,
by large-scale screening, in which restoration of genetic disorder-
inducing mutations has occurred spontaneously through mitotic
recombination. The frequency of spontaneous mitotic recombi-
nation may not be estimated properly in pluripotent stem cells and
embryonic cells in vivo and in vitro, since the event occurring in a
tiny number of cells was detected using a G418-resistant selection
with the Neo gene in many cases. In fact, mouse ESCs homozygous
for the Neo-tagged chromosomes were selected and expanded from
ESCs heterozygous for Neo-tagged chromosome by the high dose
treatment of G418 at the frequency of approximately 1610
26
[12–13]. The generation frequency of G418-resistant cells may be
underestimated to that of homologous mitotic recombination,
since some pluripotent stem cells homozygous for Neo, expressing
insufficient amount of gene product, could stop growing or be
killed. FACS analysis of mouse ESCs heterozygous for the GFP
reporter gene without drug selection detected GFP-negative cells
at the frequency of about 1610
23 (data not shown), which were
generated by homologous mitotic recombination or deletion of the
GFP gene. The circumstance evidence supports that mitotic
homologous recombination at an allele occurs at the frequency of
about 1610
24,10
25, similar to our findings using iPSCs. If so,
the genetic information may diverge between somatic cells
thorough cell divisions rather than we predicted.
An automatic genome-sorting system could make screening of
mitotic recombination-mediated genetic correction feasible. Im-
portantly, this approach dispenses with requirement for gene
therapy. As with mutation-dominant diseases such as ADPKD and
LEOPARD syndrome [18], the approach is similarly applicable to
genetic mutations in recessive diseases [19]. Once generated, the
disease-repaired iPSCs may be useful for regenerative medicine as
well as other applications. Thus, the mitotic recombination-
mediated genetic correction approach will open a new path to
clinical application for human iPSCs that is relevant to patient
groups, for which the iPSC technological revolution was believed
to hold little relevance in the clinical setting.
Materials and Methods
Ethics statement
Experiments with mice were performed according to the
institutional guideline of Kyoto University, Japan. Our animal
experiments (W-3-6) are reviewed and permitted by the animal
research committee of Kyoto University, JAPAN.
Cell culture
Pkd1(+/2) iPSC lines were established from male MEFs of
E12.5 Pkd1 knockout mouse embryos [16] by retroviral transduc-
tion of mouse OSK [20]. iPSC lines were maintained in mES
medium (DMEM/F12 supplemented with 15% FBS, L-glutamine,
penicillin-streptomycin, sodium bicarbonate, sodium pyruvate, 2-
Table 1. Frequency of spontaneous mitotic recombination at Pkd1 KO allele in iPSCs.
No. of colonies
Picked up PCR analyzed (%) Pkd1(+/R+) (Frequency) Pkd1(R2/2) (Frequency)
11,232 10,322 (91.9) 2 (1.94610
24) 1 (0.97610
24)
doi:10.1371/journal.pone.0032018.t001
Figure 3. Restoration of ADPKD phenotype in adult chimeric mice with Pkd1(+/R+) iPSCs. a, Newborn chimeric mouse (green) generated
by micro injection of Pkd1(+/2) iPSCs into host blastocyst (left panel). Contribution of Pkd1(+/R+) iPSCs into a chimeric kidney is visualized by GFP
expression (right panel). b, Contribution of iPSCs into chimeric kidneys. Degree of iPSC contribution to each kidney collected from different chimeric
mouse with Pkd1(+/2), or Pkd1(+/R+) iPSCs is indicated by a green bar. c, A hematoxylin-eosin (HE) section of Pkd1(+/2) chimeric kidney. A cyst was
recognized as diameter greater than 200 mm (left panel). Pkd1(+/2)iPSC-derived cells (green) are located on the cyst wall (white arrow heads in right
panel). Nuclei are stained as blue by DAPI. d, Frequency of cyst generation in kidneys from Pkd1(+/2), or Pkd1(+/R+) iPSC chimeric mice. The number
of cysts was counted on HE sections of kidneys, in which degree of chimerism was estimated by GFP analysis in b (33 sections from each kidney).
Error bars, s.e.m.
doi:10.1371/journal.pone.0032018.g003
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CA, USA)). For isolating colonies originated from single cells,
about 600 cells were plated into each 10 cm culture dish. The
EGFP gene was introduced into Pkd1(+/2) iPSCs by lentiviral
transduction.
Chromosome
Cells were treated with 0.075 M KCl for 8 min at room
temperature and then fixed in 3:1 methanol:acetic acid. Slides of
chromosomes prepared by an air-drying method were stained with
Hoechst 33258 (10 ng/ml) for G-banding analysis.
Genomic and RT-PCR
PCR primers used in this study are listed in Table S1. For
Genomic PCR, products were amplified with GoTaq (Promega)
by 35 cycles of reactions. For RT-PCR, total RNA of cultured cells
was extracted with TRIzol reagent (Invitrogen, USA). cDNA was
synthesized from 500 ng of total RNA with Superscript III
(Invitrogen, USA) using random hexamers following manufactur-
ers instructions. Band intensity was measured using Image J (NIH).
Southern blot hybridization
Genomic DNAs was digested with restriction enzyme(s),
separated by electrophoresis on a 1.0% agarose gel, and
transferred on a Hybond N
+ filter by alkali blotting. The
membrane was hybridized with probes labeled with
32P using
the Megaprime DNA labeling system (Amersham) overnight at
42uC following pre-hybridization treatment. The membrane was
washed twice in 26SSC/0.1% SDS at 65uC for 30 minutes and
twice in 0.16SSC/0.1% SDS at 65uC for 15 minutes. Band
intensity was measured using Image J.
Chimera
For producing chimeric embryos, Pkd1(+/2) and Pkd1(+/R+)
iPSCs ubiquitously expressing EGFP, were microinjected into
C57BL/6J6BDF1 blastocysts. 6–18 months old chimeric mice
were sacrificed for histological analyses.
Histology
For immunocytochemistry, cultured cells were fixed with 4%
PFA (paraformaldehyde)/PBS (phosphate-buffered saline) for
10 minutes at room temperature, washed with PBST (0.1%
Triton X-100 in PBS), then pre-treated with blocking solution (3%
BSA and 2% skimmed milk (DIFCO, USA) in PBST) at 4uC
overnight. The cells were then stained with fluorescence-
conjugated secondary antibodies (1:500, Invitrogen), following
immuno-reaction with primary antibodies; anti-OCT4 (1:50,
Santa Cruz Biotechnology, USA), anti-SOX2 (1:500, Abcam,
Cambridge, UK), and anti-NANOG (1:200, ReproCELL, Japan).
The cells were counterstained with DAPI (4,6-diamidino-2-
phenylindole) and mounted with SlowFade light antifade kit
(Invitrogen). Kidneys from 6–18 month old mice were fixed with
4% PFA/PBS for 4–6 hours, and embedded in paraffin. Sections
at 5 mm in thickness were stained with haematoxylin and eosin.
Supporting Information
Figure S1 Genotyping of mouse embryonic fibroblasts
(MEFs) from E12.5 embryos generated by mating of
wild-type (WT) and Pkd1(+/2) mice. Zfy is PCR product
specific to male. M; male, F; female. Male MEFs (no. 2)
heterozygous for Pkd1 knockout (KO) was used for iPSC
generation.
(TIF)
Figure S2 Karyotype of Pkd1(+/R+) iPSC. Normal karyo-
type, 2n=40,XY is shown chromosomally.
(TIF)
Figure S3 Transcription of Pkd1 mRNA in Pkd1(+/2)
and Pkd1(+/R+) iPSCs. Transcription level of mRNA
compared by band intensity is comparable between wild-type
(WT) and mutation restored Pkd1(+/R+) iPSCs, while is an
approximately half of WT in Pkd1(+/2) iPSCs.
(TIF)
Figure S4 Hematoxylin-eosin sections of kidneys at low
magnification. Cysts are frequently found in Pkd1(+/2)
chimeric kidneys, but not wild-type (WT) and mutation-restored
Pkd1(+/R+) chimeric kidneys.
(TIF)
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